TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Specificity for anemia detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Peak ethanol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve of ethanol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-day abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 24h Morphine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 48h Morphine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharyngolaryngeal discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of waistline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of transaminases level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean PASI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Non-inferiority of azithromycin to benzathine penicillin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: THF+5α‐THF/THE ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total cortisol metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dCC activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean predialysis plasma ES levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in psychiatric rating scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients meeting performance measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood loss during hemostatic process
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 1-month rates of stroke
Endpoint domain: Adverse events/effects
Primary endpoint: 1-month rates of myocardial infarction
Endpoint domain: Adverse events/effects
Primary endpoint: acute renal injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: change in thrombus mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: proportion of cases of adolescents with a mental health problem
Endpoint domain: Mortality/survival
Primary endpoint: quality of parental support provided to their adolescent
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: postoperative pneumonia rates
Endpoint domain: Mortality/survival
Primary endpoint: death or permanent residential care
Endpoint domain: Mortality/survival
Primary endpoint: institutional-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Pain during placement
Endpoint domain: Adverse events/effects
Primary endpoint: decreased fibroadenoma width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacteriologic treatment failures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: nurse visits for obesity care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Chemical castration rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median times to reach chemical castration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean PSA decreases from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of the ASI for PTSD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of moderate or severe hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage reduction of LDL-C level from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: SOD, CAT, and GSH‐Px activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Active Motion (TAM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Postoperative hydrocele occurrence
Endpoint domain: Adverse events/effects
Endpoint subdomain: null
Primary endpoint: Persistent alpha-sarcoglycan gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relief of perineal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: absolute HDL‐C change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: TG percent change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: APOB reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: incidence of abnormal ECG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: left ventricular diastolic diameter (LVDd)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: left ventricular systolic diameter (LVDs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diarrhea resolution time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Vomiting resolution time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pain intensity (visual analog scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of rescue analgesic doses
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Heart rate response to head-up tilt test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean arterial pressure response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensitivity to isoproterenol and phenylephrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety profile of treatment arms
Endpoint domain: Adverse events/effects
Primary endpoint: proportion of patients with new cerebral emboli on MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: performance of pregnancy options counseling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: unsatisfactory encounters
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: comfort delivering pregnancy test results
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Physical component score of health-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Activation of metaphoric meaning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Influence of order of information on perceptions of tamoxifen
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Lumbar Bone Mineral Density (LBMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean absolute increase in M value (deltaM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean absolute increases in MBF (deltaMBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastric volume increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Dyspeptic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Sensitivity in diagnosing caries progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive-predictive value of BTWs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative-predictive value of BTWs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 90-days mortality
Endpoint domain: Mortality/survival
Primary endpoint: admissions to the intensive care unit
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Receipt of OST (methadone or buprenorphine) at 3 month follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean excess weight loss after 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Absolute change in BMI at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in type 2 diabetes mellitus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Femoral Bone Mineral Density (Fem BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentrations of uNTx and sBAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: alpha1‐m excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: absolute gluteus maximus CSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: total gluteus medius CSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: total glutei CSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: MIP measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pain in post-anesthetic recovery room
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain evaluation 24h after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Week 8 remission rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Overall UC-DAI improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Sustained spontaneous breathing (SB) with CPAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dyspnoea severity on visual analogue scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: percentage volume maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global health status/QoL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Posttreatment social anxiety symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anhedonic depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of change in negative cognitions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BELA‐A‐k Bothered by score post‐intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: speech recognition scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sex hormone-binding globulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Geometric mean titres of neutralizing antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of EV71 infection
Endpoint domain: Adverse events/effects
Primary endpoint: BCF free survival (BCFFS) rates
Endpoint domain: Mortality/survival
Primary endpoint: AMS prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptom severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in caries
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: leakage of high sensitivity troponin T
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: leakage of pro b-type natriuretic peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 3-year all-cause death
Endpoint domain: Mortality/survival
Primary endpoint: Maternal self-confidence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: relief of depressive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: recurrence of breast cancer
Endpoint domain: Mortality/survival
Primary endpoint: death as a result of cardiovascular events
Endpoint domain: Mortality/survival
Primary endpoint: Progression in visual field (VF) loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival at 2.4 years
Endpoint domain: Mortality/survival
Primary endpoint: Episodes of unstable angina
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Freedom from angina at 3 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Leisure activities
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: 2-hour postplasma glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Matsuda whole-body insulin sensitivity index (WBISI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: true-positive interpretation probability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: false-positive interpretation probability
Endpoint domain: Adverse events/effects
Primary endpoint: Functional gain after 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone mineral density in the femur neck and hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: lag-phase duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: gastric emptying of the half meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: percentage of meal retained in the stomach 120 min postprandially
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Bacterial density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Severity score of eczema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: transcriptional activation of the peripheral innate immune system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Relative risk of achieving lipid targets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Effectiveness of nutritional intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: composite endpoint of death, myocardial infarction, or target vessel revascularization
Endpoint domain: Mortality/survival
Primary endpoint: Distant metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: CDS complication rate
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of readmission (RAD)
Endpoint domain: Resource use
Primary endpoint: Prevalence of alcohol use among pregnant women
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Propensity to develop an HRE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aphasia diagnosis validity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fentanyl consumption via PCA
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: neonatal infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Oxygen requirement during the first 24 h of CPAP delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of severe nasal injury
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of non-invasive continuous positive airway pressure (nCPAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Patients reporting feeling much better or very much better
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Relief of leading symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality-of-life parameters improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Asthma and/or recurrent wheeze
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Allergic sensitization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Propofol dose required for anesthesia induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart Rate (HR) variation during tracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: peak plasma concentration of brotizolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total area under the plasma concentration‐time curve of brotizolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: elimination half‐life of brotizolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased concentrations of IgA RF subclasses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: silent aspiration rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean GH signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disulfide-linked IRGH aggregates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proximal landing zone error vector
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of contrast medium injected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perceived degree of shared decision making (SDM)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean hot flash frequencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EPT (Eye Pain Threshold)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall agreement between histology and serological biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of markers for atrophic gastritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of markers for atrophic gastritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IGF-1 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: immunoreactive growth hormone (iGH) response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: GHBP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: SOD level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EF (Ejection Fraction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LVESVI (Left Ventricular End-Systolic Volume Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: two-year actuarial survival rate
Endpoint domain: Mortality/survival
Primary endpoint: rate of sudden death
Endpoint domain: Mortality/survival
Primary endpoint: signs of infection
Endpoint domain: Adverse events/effects
Primary endpoint: signs of cutaneous intolerance
Endpoint domain: Adverse events/effects
Primary endpoint: Root mean square of probing depth index (RMNPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: isometric muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Visual Analog Scale (VAS) for knee pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 75% or greater reduction in Psoriasis Area Severity Index (PASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postpartum haemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for further oxytocic drugs
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Fever (> 38 degrees C)
Endpoint domain: Adverse events/effects
Primary endpoint: Periodic breathing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Apneas/hypopneas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: urinary BPA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: urinary MDA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: menstrual irregularity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Stroke Self‐Efficacy Questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Recovery Locus of Control Scale scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to correct hypokalemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Referral rate to a urologist
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Anorectal angle at rest, during squeeze, cough, and straining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes